931 related articles for article (PubMed ID: 16793845)
1. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
2. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
McLaughlin VV
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
4. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
5. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases.
Cozzi F; Montisci R; Marotta H; Bobbo F; Durigon N; Ruscazio M; Sfriso P; Iliceto S; Todesco S
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():49-53. PubMed ID: 16919011
[TBL] [Abstract][Full Text] [Related]
6. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials.
Avouac J; Wipff J; Kahan A; Allanore Y
Ann Rheum Dis; 2008 Jun; 67(6):808-14. PubMed ID: 17901091
[TBL] [Abstract][Full Text] [Related]
7. Survival with first-line bosentan in patients with primary pulmonary hypertension.
McLaughlin VV; Sitbon O; Badesch DB; Barst RJ; Black C; Galiè N; Rainisio M; Simonneau G; Rubin LJ
Eur Respir J; 2005 Feb; 25(2):244-9. PubMed ID: 15684287
[TBL] [Abstract][Full Text] [Related]
8. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
Ahmadi-Simab K; Hellmich B; Gross WL
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
[TBL] [Abstract][Full Text] [Related]
9. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
[TBL] [Abstract][Full Text] [Related]
10. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.
Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
Heart; 2007 Mar; 93(3):350-4. PubMed ID: 16980516
[TBL] [Abstract][Full Text] [Related]
11. [Two-years therapy with bosentan of pulmonary arterial hypertension related to connective tissue diseases].
Marotta H; Montisci R; Tiso F; Pontarollo S; Rizzo M; Tona F; Iliceto S; Cozzi F
Reumatismo; 2007; 59(4):299-303. PubMed ID: 18157286
[TBL] [Abstract][Full Text] [Related]
12. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.
Simonneau G; Galiè N; Jansa P; Meyer GM; Al-Hiti H; Kusic-Pajic A; Lemarié JC; Hoeper MM; Rubin LJ
Int J Cardiol; 2014 Mar; 172(2):332-9. PubMed ID: 24525158
[TBL] [Abstract][Full Text] [Related]
13. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
[TBL] [Abstract][Full Text] [Related]
14. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
[TBL] [Abstract][Full Text] [Related]
15. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
van Loon RL; Hoendermis ES; Duffels MG; Vonk-Noordegraaf A; Mulder BJ; Hillege HL; Berger RM
Am Heart J; 2007 Oct; 154(4):776-82. PubMed ID: 17893008
[TBL] [Abstract][Full Text] [Related]
16. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
Heart; 2005 Nov; 91(11):1447-52. PubMed ID: 15761050
[TBL] [Abstract][Full Text] [Related]
17. The Bosentan Patient Registry: long-term survival in pulmonary arterial hypertension.
Keogh A; Strange G; McNeil K; Williams TJ; Gabbay E; Proudman S; Weintraub RG; Wlodarczyk J; Dalton B
Intern Med J; 2011 Mar; 41(3):227-34. PubMed ID: 20002851
[TBL] [Abstract][Full Text] [Related]
18. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
19. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.
Oudiz RJ; Schilz RJ; Barst RJ; Galié N; Rich S; Rubin LJ; Simonneau G;
Chest; 2004 Aug; 126(2):420-7. PubMed ID: 15302727
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era.
Jacobs W; Boonstra A; Brand M; Rosenberg DM; Schaaf B; Postmus PE; Vonk Noordegraaf A
J Heart Lung Transplant; 2010 Oct; 29(10):1150-8. PubMed ID: 20580264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
